Data from a new mouse study indicated that a mother’s exposure to air pollution during pregnancy can increase the risk for asthma in her adult offspring. Specifically, the study showed that adult mice with no direct exposure to pollution, whose mothers were exposed to particulate air pollution, exhibited heightened allergic airways disease.
Advertisement
New ASCENT-04 data could shift first-line care in PD-L1+ TNBC. Dr. Rebecca Shatsky shares real-world insights from ASCO 2025.
Treatment with a finerenone-empagliflozin combo leads to greater decreases in albuminuria in CKD and type 2 diabetes.
Pegcetacoplan reduced proteinuria and stabilized eGFR in adolescent patients with C3G or primary IC-MPGN.
An analysis confirmed the efficacy and safety of pegcetacoplan for patients with C3G/IC-MPGN and nephrotic range proteinuria.
The nanoparticle design delivers mRNA to resting CD4+ T cells, enabling HIV reactivation without toxicity.
Treatment effects of nefecon were consistent independent of baseline eGFR among patients with IgAN.
Infliximab therapy for Crohn’s disease is linked to a high risk for IgAN, a study found.
Arm D of the SEQUOIA trial evaluated the combo in patients with either del(17p) or TP53 mutation, both mutations, or neither.
DocWire Content Partners
Gain insights from The CardioNerds, a group of cardiology experts who aim to democratize cardiovascular education.
Fundamentals, core concepts, and important management approaches in the field of hematology and oncology
Dr. Chadi Nabhan, a renowned voice in hematology and oncology, tackles a multitude of relevant health care topics.
Drs. Rohit Gosain and Rahul Gosain discuss practice-changing data and standards of oncology care.
Dr. Hady Lichaa is an interventional cardiologist specializing in complex coronary interventions.
Review important issues in the rheumatology space, including lupus, rheumatoid arthritis, and more, from Dr. Maheswaranathan.
Powered by DocWire News
The Latest From GI Oncology Now
Suvemcitug, envafolimab, and FOLFIRI may serve as a new second-line treatment option for cold tumors.
KRASG12C inhibitors can have reduced efficacy in patients with alterations in KRAS, EGFR, and other genes.
Complete responders with HCC have prolonged survival and durable disease control even after therapy has been discontinued.
The primary objective of median PFS was significantly longer for patients treated with 177Lu-edotreotide.
The safety profile of the combination was consistent with known profiles, and no new safety findings were observed.
Older patients in their 70s with extrahepatic CCA have a higher rate of choledocholithiasis.
The Latest From Heme Today
Arm D of the SEQUOIA trial evaluated the combo in patients with either del(17p) or TP53 mutation, both mutations, or neither.
The results are reported from an international cohort and support adding the agent to plasma exchange and immunosuppression.
MANIFEST-2 compares pelabresib plus ruxolitinib with placebo plus ruxolitinib for JAK-inhibitor-naive disease.
In a phase 3 study, patients who received recombinant ADAMTS13 did not experience acute TTP events during prophylaxis.
Iron deficiency anemia was associated with 39% increased odds of stroke, independent of the risk factors for stroke.
While cytoreductive drugs did not reduce thrombosis risk, interferon significantly improved myelofibrosis-free survival.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.